Venture capital firm EQT Life Sciences, through its LSP Dementia Fund, is participating in a $39 million Series A funding round for Aerska, a company focused on systematically delivering RNA medicines to the brain. This was announced in a press release.

With this round, Aerska has raised a total of $60 million in capital, building on a seed round completed in October 2025. Representatives from EQT Life Sciences will take two seats on Aerska's board of directors.